image credit: Ricardo Ricote Rodríguez / Flickr

Another High-Profile Spark Therapeutics Executive Departs As Merger with Roche Continues

February 27, 2020

Via: BioSpace

Another high-profile member of the Spark Therapeutics leadership team is departing the company ahead of its merger with Swiss pharma giant Roche. After four years with the gene therapy company, Chief Medical Officer Kathleen Reape will resign her position.

Reape has been with Spark since 2016. She first joined as head of clinical research and development in 2016 and then became CMO in 2018. Her departure was first reported by Fierce Biotech. A spokesperson for Roche confirmed the departure with the outlet and called her a “valuable member” of the company. The Roche spokesperson added that Reape “leaves behind a skilled team of professionals who will continue advancing our important work for patients and families.”

Read More on BioSpace